I believe it was Stephen King who once said: “The
road to hell is paved with adverbs.” In legal writing, the same can be said for
adjectives. I—like every other legal writing “expert” I know—caution against
the use of adjectives and adverbs. The most effective legal writers don’t tell
the reader: “This was a terrible accident”; they show the reader what
made the accident terrible (The investigating officer described the
accident as “the worse [he’d] seen in [his] 15 years of accident investigation.”).
Paul Clement |
But Paul Clement, former Solicitor General, one of the nation’s best Supreme
Court advocates, and an excellent writer, uses adjectives and adverbs
effectively for emphasis. Take the following from his brief on behalf of
Allergan in Allergan v. United States,
an important First Amendment case involving a dispute over drug companies’
ability to speak to physicians about off-label uses of their drugs:
When the Government starts picking favored speakers,
First Amendment values are in grave
danger.
The inclusion of the modifier “grave” takes the sentence up a notch—First Amendment free speech rights aren’t just in
danger (which is bad enough)—they’re in grave
danger (even worse!).
Clement uses other descriptors strategically
throughout the Allergan brief with
similar results:
“It is perfectly
lawful for physicians to prescribe Botox® for [spasticity] and other
off-label uses.”
The Government opens its brief by ominously warning that Allergan has
launched a “sweeping assault” on the framework for new drug approval that the
Kefauver-Harris Amendments to the FDCA established in 1962.
The Government also has studiously avoided taking a litigation position here that might
bind either FDA or DOJ in the future. The Government never squarely states an official position that FDA’s regulations do not
prohibit non-promotional speech...
The overbreadth problem posed by the Government’s expansive conception of “promotional”
speech is particularly problematic because
it infringes upon fully-protected speech.
First, the FDCA’s “new drug” and misbranding rules
trigger First Amendment scrutiny because they are irretrievably content-based....
The Government has not come close to proving that
FDA’s blanket suppression of
off-label speech survives First Amendment scrutiny.
FDA’s indiscriminate
prohibitions of off-label speech manifestly fail this test.
There is “no hint,” however, “that the Government
even considered these or any other alternatives” before enacting its draconian regulations suppressing
virtually all off-label speech.
It is thus not clear whether FDA ever had a coherent reason for suppressing
virtually all off-label speech, or if this approach was less a conscious choice than an inadvertent byproduct of regulations
aimed at mitigating other harms.
This is why FDA’s approval process is extremely rigorous.
The staggering
breadth of the “intended use” regulations is also irrational in light of
the legal and practical reality that off-label use is lawful and often
necessary to appropriate patient care.
FDA has nonetheless chosen the route of censorship, completely prohibiting all forms of
off-label advertisement, even where the advertised use is medically accepted
and the advertisement is truthful and directed at physicians rather than
consumers.
Clement is a master of this technique, employing it
selectively and strategically for his most important points. If you’re
interested in testing it out, follow that lead.
While the road to hell may be paved with adverbs (and
adjectives), as Clement demonstrates, the road to a good brief may be paved
with a few of them as well!
Happy Friday!